A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer®) vs iron gluconate (Ferrlecit®) in haemodialysis patients treated with rHuEpo

Nephrology Dialysis Transplantation

Volumn 16, Issue 6, 2001, Pages 1239-1244

  Kosch, Markus ^a   Bahner, Udo ^b   Bettger, Helga ^b   Matzkies, Fritz ^a   Teschner, Markus ^b   Schaefer, Roland M ^a,c  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b KfH Dialysis Centre   (Germany)

^c Innere Medizin D   (Germany)

Author keywords

Anaemia; Haemodialysis; Iron gluconate; Iron sucrose; Recombinant human erythropoietin

Indexed keywords

ANTIANEMIC AGENT; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERRITIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; SODIUM CHLORIDE; TRANSFERRIN;

ADULT; AGED; ANAPHYLAXIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DILUTION; DOSE RESPONSE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; FLUSHING; HEMODIALYSIS PATIENT; HUMAN; HYPOTENSION; INJECTION; IRON OVERLOAD; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARAMETER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

EID: 0034965685     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.6.1239     Document Type: Article

References (26)

1. The use of iron in patients on chronic dialysis: Mistakes and misconceptions
2. Blood loss during maintenance hemodialysis
3. Dialyzer blood loss
4. Erythropoietin and iron
5. How to diagnose and correct iron deficiency during rhEPO therapy
6. Intravenous iron dextran in clinical medicine
7. A surveillance programme on Imferon
8. The safety of intravenous iron dextran in hemodialysis patients
9. Agents affecting volume and composition of body fluids
10. Serious adverse reactions after intravenous ferric gluconate
11. Sodium ferric gluconate complex is safe and effective in haemodialysis patients: North American clinical trial
12. Intravenous ferric saccharate as an iron supplement in dialysis patients
13. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial
14. Intravenous iron hydroxysaccharate: Establishing the optimum dose
15. Iron absorption in erythropoietin-treated haemodialysis patients: Effects of iron availability, inflammation and aluminium
16. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin
17. A randomized controlled study of iron supplementation in patients treated with erythropoietin
18. Monitoring of iron requirements in renal patients on erythropoietin
19. European best practice guidelines for the management of anaemia in patients with chronic renal failure
20. The economic impact of increased usage of intravenous iron dextran (IV Fe) and subcutaneous erythropoietin (SQ EPO) on the total cost of anemia treatment in hemodialysis (HD) patients
21. Safety of intravenous injection of iron saccharate in hemodialysis patients
22. ®) in haemodialysis patients
23. Safety aspects of parenteral iron in patients with end-stage renal disease
24. I.v. iron dosing patterns and mortality
25. Frequent i.v. iron dosing is associated with higher infectious death